Replenish. Relieve. Restore. Repeat, safely.2-4

Open-label extension study was not designed to establish long-term efficacy of a repeat injection series of EUFLEXXA.
Error bars indicate 95% confidence intervals.

EUFLEXXA superiority to saline was demonstrated in a 26-week, randomized, double-blind, saline-controlled study4

  • In a continuation of the 26-week FLEXX trial (N=588), the 26-week open-label FLEXX extension trial (N=219) showed that repeat treatment with EUFLEXXA was safe for an additional 26 weeks*4
  • Patients should be assessed for retreatment at 6 months4

*All 516 patients who completed the 26-week FLEXX trial were offered treatment with EUFLEXXA 26 weeks after their first treatment. For those patients who received a series of 3 sodium chloride injections in the FLEXX trial and went on to receive EUFLEXXA in the 26-week FLEXX extension trial (n=214), this was their first 3-injection treatment with EUFLEXXA. For those who had previously received EUFLEXXA in the FLEXX trial, this was a repeated series of 3 injections.3,4

EUFLEXXA superiority to saline was demonstrated in a 26-week, randomized, double-blind, saline-controlled study4

  • In a continuation of the 26-week FLEXX trial (N=588), the 26-week open-label FLEXX extension trial (N=219) showed that repeat treatment with EUFLEXXA was safe for an additional 26 weeks*4
  • Patients should be assessed for retreatment at 6 months4

Please See Important Safety Information and Full Prescribing Information.

INDICATION

EUFLEXXA® [1% sodium hyaluronate] is indicated for the treatment of pain in osteoarthritis [DA] of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics [eg, acetaminophen].

IMPORTANT SAFETY INFORMATION

EUFLEXXA is contraindicated in patients who have a known hypersensitivity to hyaluronate preparations or who have knee joint infections, infections, or skin disease in the area of the injection site.

EUFLEXXA should not be administered through a needle previously used with medical solutions containing benzalkonium chloride. Do not use skin disinfectants for skin preparation that contain quaternary ammonium salts.

Do not inject intravascularly due to potential for systemic adverse events.

The safety and effectiveness of injection in conjunction with other intra-articular injectables, or into joints other than the knee have not been studied. Remove any joint effusion prior to injecting. Transient pain or swelling of the injected joint may occur after intra-articular injection with EUFLEXXA.

The most common adverse events related to EUFLEXXA injections reported in 12- and 26-week clinical studies were arthralgia, back pain, pain in extremity, musculoskeletal pain, and joint swelling. In an open-label extension of the 26-week clinical study with repeat series of injections, the most common adverse events related to EUFLEXXA at Week 52 were arthralgia and joint swelling.

Please see Full Prescribing Information.

Please see Full Prescribing Information.